Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-02-28

FDA Approved: AGRYLIN — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

FDA approves a supplemental application for AGRYLIN (anagrelide hydrochloride) submitted by Takeda, resulting in changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGRYLIN (ANAGRELIDE HYDROCHLORIDE)

Snippet

SUPPL AP for AGRYLIN (ANAGRELIDE HYDROCHLORIDE)